| A crosstalk established between tumor microenvironment and tumor cells leads to contribution or inhibition of
tumor progression. Mesenchymal stem cells (MSCs) are critical cells that fundamentally participate in modulation of
the tumor microenvironment, and have been reported to be able to regulate and determine the final destination of
tumor cell. Conflicting functions have been attributed to the activity of MSCs in the tumor microenvironment; they
can confer a tumorigenic or anti-tumor potential to the tumor cells. Nonetheless, MSCs have been associated with
a potential to modulate the tumor microenvironment in favouring the suppression of cancer cells, and promising
results have been reported from the preclinical as well as clinical studies. Among the favourable behaviours of MSCs,
are releasing mediators (like exosomes) and their natural migrative potential to tumor sites, allowing efficient drug
delivering and, thereby, efficient targeting of migrating tumor cells. Additionally, angiogenesis of tumor tissue has
been characterized as a key feature of tumors for growth and metastasis. Upon introduction of first anti-angiogenic
therapy by a monoclonal antibody, attentions have been drawn toward manipulation of angiogenesis as an attractive
strategy for cancer therapy. After that, a wide effort has been put on improving the approaches for cancer therapy
through interfering with tumor angiogenesis. In this article, we attempted to have an overview on recent findings
with respect to promising potential of MSCs in cancer therapy and had emphasis on the implementing MSCs to
improve them against the suppression of angiogenesis in tumor tissue, hence, impeding the tumor progression. |